⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8706004 | 0.83 | NPC1 (0.43) | — | |
| SCHEMBL4729951 | 0.79 | — | — | |
| SCHEMBL4486306 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL11786036 | 0.77 | L3MBTL1 (0.60) | — | |
| SCHEMBL110811 | 0.74 | NPC1 (0.53) | — | |
| SCHEMBL9374840 | 0.74 | PARP1 (0.35) | — | |
| SCHEMBL13631428 | 0.74 | NPC1 (0.53) | — | |
| SCHEMBL1476834 | 0.73 | — | — | |
| SCHEMBL8586691 | 0.72 | RAB9A (0.48) | — | |
| SCHEMBL382018 | 0.71 | CA12 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| CN-109311887-B | Pyrazolo [1,5-a ] pyrimidinecarboxamide compounds and their use in the treatment of medical conditions | BIAL研发投资股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-12-07 | — | — | US | disclosed |
| US-10934298-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | BIAL—BioTech Investments, Inc. (PT) | 2021-03-02 | — | — | US | disclosed |
| US-20190330213-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-10-31 | — | — | US | disclosed |
| EP-3440080-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Lysosomal Therapeutics Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| CN-109311887-A | Pyrazolo [1,5-a] pyrimidine radicals benzamide compound and they treatment medical conditions in purposes | 溶酶体治疗股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-9840510-B1 | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| WO-2017176960-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2001007409-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA UK LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| US-6114358-A | Thrombin inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | disclosed |
| CN-1228783-A | Novel thrombin inhibitors | BASF AG (DE) | 1999-09-15 | — | — | CN | disclosed |
| WO-1998042323-A1 | STABILIZED UREASE INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-01 | — | — | WO | disclosed |